InvestorsHub Logo
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Thursday, 03/31/2022 2:42:41 PM

Thursday, March 31, 2022 2:42:41 PM

Post# of 3999
Summary

The PRX-102 studies have produced readouts providing additional support for the safety, efficacy and potential for
superiority compared to Fabrazyme. BRIGHT results were released just a few weeks ago and topline for the important BALANCE study is expected in the next several days. Results from the BALANCE study will be included
with the upcoming 2H:22 resubmission of the BLA to the FDA for PRX-102. On the other side of the Atlantic, Protalix submitted its MAA to the EMA and should see a response from the European agency around year end. Based
on our forecasts, timeline and estimates, we maintain our target price of $11.00 per share.

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03312022_PLX_Vandermosten.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News